Munich, Germany, 17 October 2011 - Genomatix is among the 41 partners of the BLUEPRINT epigenome consortium funded by the European Commission as a high impact project within its seventh framework program (FP7). Genomatix' contributions will be next generation sequencing data analysis and the development of an intuitive GUI to make the project's results easily accessible to researchers within and outside the consortium.
"To be part of, and to get substantial funding from this ambitious project, is a pleasant affirmation of our research and development efforts to provide high quality data analysis in a very usable way for biologists", says Dr. Martin Seifert, CEO of Genomatix. "We highly appreciate the European Commission's commitment to support SMEs in its current FP7 program, as it enables us to participate in a high-profile research project that will generate fascinating new insights into epigenomics. It is of direct relevance to our business, as it will help us to offer our customers an even broader biological data background for their research. This will improve the understanding of molecular processes and hence lead to better biomedical applications."
Dr. Korbinian Grote, product manager at Genomatix adds: "The BLUEPRINT epigenome project is a chance to work with high-quality epigenomics data from renowned institutions and labs from all over Europe. It will help us to further improve our existing line of next generation sequencing analysis products and will lead to the implementation of new ideas tailored towards the integration of epigenomic data into our interfaces and visualizations."
|Contact: Korbinian Grote|
Genomatix Software GmbH